Singapore Clinical Research Institute

Established in 2008, the Singapore Clinical Research Institute (SCRI) is a national academic clinical research organisation dedicated to enhancing the standards of human clinical research. It provides core services (including clinical, biostatistical data, project management expertise, medical informatics solutions) and infrastructure at a national level for late phase clinical research. SCRI further took on a national clinical trial coordinating role in 2014; actively engaging companies and industries, and working closely with the IMUs, BMS IPO, EDB and MOH to foster public-private collaborations as well as provide leadership in the operational and methodological aspects of clinical trials. These efforts have helped Singapore become a more attractive place to private sector investors and will continue to contribute to the enhancement of the local clinical trials landscape in the years to come. SCRI Pte Ltd is a Tier-1 subsidiary of MOH Holdings (MOHH) and was converted to a holding company in 2016 to house NHIC Singapore as a business unit. 

Please click here for more information.

Last updated: 9 May 2018